NEW YORK, Nov. 2 – Variagenics recorded a drop in revenues and a widened net loss for the third quarter 2001 compared with the same period last year, the company said.

The Cambridge, Mass.-based pharmacogenomics company said revenues for the three months ended Sept. 30 fell to $600,000 from $800,000 one year earlier. Basic and diluted net loss, meanwhile, jumped to $6.6 million, or $0.28 per share, from $6.4 million, or $0.35 for the third quarter of 2000.

Still, the company remained optimistic about its outlook.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.